Fidia Pharma USA has announced the launch of Triluron (sodium hyaluronate), a hyaluronic acid (HA) based intra-articular viscosupplement.
Triluron is indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and to simple analgesics (eg, acetaminophen). The product contains sodium hyaluronate 20mg that is administered by intra-articular injection at weekly intervals for a total of 3 injections; the effectiveness of a single treatment cycle of less than 3 injections has not been established.
The chemical formulation of Triluron is identical to Hyalgan, the Company’s 5-injection regimen. In terms of efficacy, Triluron was found to be noninferior to Hyalgan based on a retrospective analysis of data collected from 2 randomized controlled trials.
Triluron is extracted from rooster combs so healthcare providers should use caution when injecting the product into patients who are allergic to avian proteins, feathers, and egg products.
The product is supplied in 2mL vials or 2mL prefilled syringes and is intended for single use. If treatment is bilateral, a separate vial/syringe should be used for each knee.
For more information visit fidiapharma.us.
This article originally appeared on MPR